JP2006515599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515599A5 JP2006515599A5 JP2005502148A JP2005502148A JP2006515599A5 JP 2006515599 A5 JP2006515599 A5 JP 2006515599A5 JP 2005502148 A JP2005502148 A JP 2005502148A JP 2005502148 A JP2005502148 A JP 2005502148A JP 2006515599 A5 JP2006515599 A5 JP 2006515599A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- seq
- group
- appendix
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 103
- 230000000324 neuroprotective effect Effects 0.000 claims 35
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims 26
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 26
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 26
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 23
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 16
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 16
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 16
- 230000002265 prevention Effects 0.000 claims 15
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 12
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 12
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 12
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical group OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 12
- 125000000028 D-cysteine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(S[H])([H])[H] 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 108010092674 Enkephalins Proteins 0.000 claims 10
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims 10
- 102400000096 Substance P Human genes 0.000 claims 10
- 101800003906 Substance P Proteins 0.000 claims 10
- -1 8-hydroxy-5-quinolinylmethylene group Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 8
- XIXFNVDWEWCEOI-UHFFFAOYSA-N 5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]quinolin-8-ol Chemical compound C1CN(CCO)CCN1CC1=CC=C(O)C2=NC=CC=C12 XIXFNVDWEWCEOI-UHFFFAOYSA-N 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims 7
- 125000004193 piperazinyl group Chemical group 0.000 claims 7
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 230000032683 aging Effects 0.000 claims 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims 5
- 230000009759 skin aging Effects 0.000 claims 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 4
- 206010065973 Iron Overload Diseases 0.000 claims 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 206010048610 Cardiotoxicity Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010017533 Fungal infection Diseases 0.000 claims 3
- 208000018565 Hemochromatosis Diseases 0.000 claims 3
- 208000002903 Thalassemia Diseases 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 3
- 230000002424 anti-apoptotic effect Effects 0.000 claims 3
- 231100000259 cardiotoxicity Toxicity 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 229910052742 iron Inorganic materials 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- 230000036542 oxidative stress Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 230000037380 skin damage Effects 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 claims 2
- LQUSVSANJKHVTM-UHFFFAOYSA-N 3-hydroxy-3h-pyridin-4-one Chemical compound OC1C=NC=CC1=O LQUSVSANJKHVTM-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 2
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 2
- 229930195710 D‐cysteine Natural products 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 2
- 235000013878 L-cysteine Nutrition 0.000 claims 2
- 239000004201 L-cysteine Substances 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000010362 Protozoan Infections Diseases 0.000 claims 2
- 229960003767 alanine Drugs 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 238000002655 chelation therapy Methods 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 230000002431 foraging effect Effects 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 125000001165 hydrophobic group Chemical group 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000004321 preservation Methods 0.000 claims 2
- 230000004224 protection Effects 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- PZPKPRRSGFAFHY-UHFFFAOYSA-N 2-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]quinolin-8-ol Chemical compound C1CN(CCO)CCN1CC1=CC=C(C=CC=C2O)C2=N1 PZPKPRRSGFAFHY-UHFFFAOYSA-N 0.000 claims 1
- QVXIZJHZWYLVET-UHFFFAOYSA-N 3-hydroxy-2-methyl-3h-pyridin-4-one Chemical group CC1=NC=CC(=O)C1O QVXIZJHZWYLVET-UHFFFAOYSA-N 0.000 claims 1
- ZCUUVWCJGRQCMZ-UHFFFAOYSA-N 3-hydroxypyridin-4-one Natural products OC1=CC=NC=C1O ZCUUVWCJGRQCMZ-UHFFFAOYSA-N 0.000 claims 1
- JWUOZHTYFQHGAB-UHFFFAOYSA-N 5-[(4-prop-2-ynylpiperazin-1-yl)methyl]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CN1CCN(CC#C)CC1 JWUOZHTYFQHGAB-UHFFFAOYSA-N 0.000 claims 1
- 102220616205 CCR4-NOT transcription complex subunit 4_M18A_mutation Human genes 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 102220485863 Dihydropteridine reductase_M28A_mutation Human genes 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102220617837 Putative protein CLUHP3_M19A_mutation Human genes 0.000 claims 1
- 102220507208 Rab11 family-interacting protein 1_M21A_mutation Human genes 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010038997 Retroviral infections Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102220568769 Synaptic vesicle membrane protein VAT-1 homolog_M27A_mutation Human genes 0.000 claims 1
- 102220594896 Vasopressin-neurophysin 2-copeptin_M20A_mutation Human genes 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000009920 chelation Effects 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 229940043239 cytotoxic antineoplastic drug Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000003916 ethylene diamine group Chemical group 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 208000028172 protozoa infectious disease Diseases 0.000 claims 1
- 150000005299 pyridinones Chemical group 0.000 claims 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical group C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 0 C**c(cc1)ccc1O Chemical compound C**c(cc1)ccc1O 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42431302P | 2002-11-07 | 2002-11-07 | |
| US60/424,313 | 2002-11-07 | ||
| US50412603P | 2003-09-22 | 2003-09-22 | |
| US60/504,126 | 2003-09-22 | ||
| PCT/IL2003/000932 WO2004041151A2 (en) | 2002-11-07 | 2003-11-07 | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010238156A Division JP2011079834A (ja) | 2002-11-07 | 2010-10-25 | 神経保護鉄キレート剤及びそれを含む医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006515599A JP2006515599A (ja) | 2006-06-01 |
| JP2006515599A5 true JP2006515599A5 (https=) | 2006-12-07 |
| JP4757024B2 JP4757024B2 (ja) | 2011-08-24 |
Family
ID=32314530
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005502148A Expired - Fee Related JP4757024B2 (ja) | 2002-11-07 | 2003-11-07 | 神経保護鉄キレート剤及びそれを含む医薬組成物 |
| JP2010238156A Abandoned JP2011079834A (ja) | 2002-11-07 | 2010-10-25 | 神経保護鉄キレート剤及びそれを含む医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010238156A Abandoned JP2011079834A (ja) | 2002-11-07 | 2010-10-25 | 神経保護鉄キレート剤及びそれを含む医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8058442B2 (https=) |
| EP (1) | EP1565185A4 (https=) |
| JP (2) | JP4757024B2 (https=) |
| AU (1) | AU2003282337B2 (https=) |
| CA (1) | CA2505476C (https=) |
| IL (1) | IL168419A (https=) |
| WO (1) | WO2004041151A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004020644A1 (de) * | 2004-04-22 | 2005-11-17 | Coty B.V. | Verfahren zur Bestimmung eines UVA- und UVB-Strahlung erfassenden integralen Sonnenschutzfaktors |
| WO2007095728A1 (en) * | 2006-02-22 | 2007-08-30 | Arnold Munnich | The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron |
| BRPI0715123A2 (pt) * | 2006-08-04 | 2013-06-04 | Novartis Ag | tratamento de disfunÇço endàcrina usando quelantes de ferro |
| FR2913976B1 (fr) * | 2007-03-23 | 2013-04-26 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers. |
| CN101679263B (zh) | 2007-03-28 | 2014-01-15 | 阿普泰克斯科技公司 | 去铁酮的氟化衍生物 |
| EP2268282B1 (en) * | 2008-04-25 | 2014-10-29 | Apotex Technologies Inc. | Liquid formulation for deferiprone with palatable taste |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CA2750599A1 (en) * | 2009-01-26 | 2010-07-29 | Michael Spino | Use of deferiprone for treatment and prevention of iron-related eye disorders |
| CA2751033A1 (en) | 2009-01-29 | 2010-08-05 | Yeda Research And Development Co. Ltd. | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them |
| WO2010092419A1 (en) * | 2009-02-12 | 2010-08-19 | Assistance Publique - Hopitaux De Paris | Combined treatment of multiple sclerosis |
| WO2010147621A1 (en) * | 2009-06-16 | 2010-12-23 | The Trustees Of Columbia University In The City Of New York | Methods for ameliorating adverse effects associated with transfusion of aged red blood cells |
| GEP20146008B (en) | 2009-07-03 | 2014-01-10 | Apotex Tech Inc | Fluorinated derivatives of 3-hydroxypyridin-4-ones |
| US20140186280A1 (en) * | 2010-08-13 | 2014-07-03 | Varinel Inc | Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof |
| CN103298790A (zh) * | 2010-08-13 | 2013-09-11 | 维里奈奥公司 | 神经保护作用和神经修复作用的铁螯合剂和单胺氧化酶抑制剂及其用途 |
| WO2012104204A1 (en) | 2011-01-31 | 2012-08-09 | Vifor (International) Ag | Iron-carbohydrate complex compounds for the intravenous therapy of malaria |
| CA2826192A1 (en) * | 2011-01-31 | 2012-08-09 | The Government Of The United States, As Represented By The Secretary Of The Army | Methods and compositions for treating bacterial infections with iron chelators |
| WO2013115793A1 (en) | 2012-01-31 | 2013-08-08 | Varinel, Inc. | Iron chelators and uses thereof |
| EP2727916A1 (en) | 2012-10-30 | 2014-05-07 | Universitat Autònoma de Barcelona | Neuroprotective multi-target directed drugs |
| WO2014179139A2 (en) * | 2013-04-30 | 2014-11-06 | Albert Einstein College Of Medicine Of Yeshiva University | TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION |
| US20160271248A1 (en) * | 2013-10-03 | 2016-09-22 | Drexel University | Cxcr4 up- and down-regulation for treatment of diseases or disorders |
| US11504346B2 (en) | 2013-11-03 | 2022-11-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redox-activated pro-chelators |
| US12383518B2 (en) | 2013-11-03 | 2025-08-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Disulfide-masked pro-chelator compositions and methods of use |
| JP6612131B2 (ja) | 2014-01-17 | 2019-11-27 | セルスペクト株式会社 | 鉄（ｉｉ）イオン検出剤及びそれを用いた検出方法 |
| WO2016029158A2 (en) * | 2014-08-21 | 2016-02-25 | Collaborative Medicinal Development Llc | Compositions and methods for extending lifespan |
| GB201420348D0 (en) * | 2014-11-17 | 2014-12-31 | Univ Northumbria Newcastle | Compounds for treating neurodegenerative diseases |
| EP3377094B1 (en) * | 2015-11-19 | 2021-04-28 | Universität Basel | Virulence attenuated bacteria for treatment of malignant solid tumors |
| CN106279582B (zh) * | 2016-08-15 | 2018-04-17 | 浙江大学 | 铜离子响应性的两亲性聚合物和作为抗肿瘤药物和载体的应用 |
| JP2018188419A (ja) * | 2017-05-11 | 2018-11-29 | 株式会社ダステック | 抗腫瘍活性、抗菌活性、および／または抗ウイルス活性を有し、副作用が低減された鉄キレート剤を含む医薬組成物 |
| WO2018207852A1 (ja) * | 2017-05-11 | 2018-11-15 | 株式会社ダステック | 抗腫瘍活性、抗菌活性、および／または抗ウイルス活性を有し、副作用が低減された鉄キレート剤を含む医薬組成物 |
| MD3684344T2 (ro) | 2017-10-25 | 2025-09-30 | Chiesi Farm Spa | Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora |
| WO2020061474A1 (en) * | 2018-09-20 | 2020-03-26 | Tautona Group Ip Holding Company, L.L.C. | Iron chelating compounds for treating aesthetic skin conditions |
| CN109761964B (zh) * | 2018-12-29 | 2021-02-02 | 浙江工业大学 | 香豆素骈3-羟基吡啶-4-酮的衍生物及其制备方法与应用 |
| US12150958B2 (en) * | 2020-01-08 | 2024-11-26 | The Sallie Astor Burdine Breast Foundation | Compositions and methods for treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and associated methods for preparing said compositions |
| CN111170936B (zh) * | 2020-01-19 | 2021-01-01 | 杭州泽德医药科技有限公司 | 3,4-二羟基-n-(1’-苄基-2’-羟乙基)-2-甲基吡啶氯化物及制备和应用 |
| WO2022015983A1 (en) * | 2020-07-15 | 2022-01-20 | Memorial Sloan-Kettering Cancer Center | Methods of treating leptomeningeal metastasis |
| CN112521331B (zh) * | 2020-12-16 | 2022-07-19 | 浙江工业大学 | 一种吡啶酮一位炔胺修饰衍生物及其制备方法与应用 |
| CN112552232B (zh) * | 2020-12-16 | 2022-11-25 | 浙江工业大学 | 一种吡啶酮六位炔胺修饰衍生物及其制备方法与应用 |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| CN114716366B (zh) * | 2022-04-13 | 2023-12-26 | 浙江大学 | 3-羟基吡啶-4-酮类衍生物及在抑制肾细胞铁死亡中的应用 |
| CN117105853A (zh) * | 2023-08-28 | 2023-11-24 | 浙江工业大学 | 3-羟基吡啶-4(h)-酮类衍生物及其制备方法与应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3297527A (en) | 1963-10-09 | 1967-01-10 | Parke Davis & Co | Propargylamine as an anti-depressant |
| RO63861A2 (fr) | 1974-09-26 | 1979-01-15 | Medicamente Terapia Intreprind | Derive du hydrazide d'acide isonicotinique et procede de preparation |
| GR78491B (https=) | 1982-03-24 | 1984-09-27 | Nat Res Dev | |
| US4861800A (en) | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| US5151449A (en) | 1990-08-31 | 1992-09-29 | Deprenyl Animal Health, Inc. | Use of L-deprenyl for retention of specific physiological functions |
| US5225446A (en) | 1990-08-31 | 1993-07-06 | Deprenyl Animal Health, Inc. | Use of 1-deprenyl for retention of specific physiological functions |
| CA2039194C (en) | 1990-08-31 | 1997-01-28 | Norton W. Milgram | Uses of l-deprenyl and compositions for same |
| US5192808A (en) | 1990-08-31 | 1993-03-09 | Deprenyl Animal Health, Inc. | Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease) |
| US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
| US5532416A (en) | 1994-07-20 | 1996-07-02 | Monsanto Company | Benzoyl derivatives and synthesis thereof |
| US5242950A (en) | 1992-04-23 | 1993-09-07 | Somerset Pharmaceuticals, Inc. | Treatment of macular degeneration |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| US6251938B1 (en) | 1996-12-18 | 2001-06-26 | Teva Pharmaceutical Industries, Ltd., | Phenylethylamine derivatives |
| DE69738275T2 (de) | 1996-12-18 | 2008-08-28 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| GB9711093D0 (en) | 1997-05-29 | 1997-07-23 | British Tech Group | Novel orally active iron (III) chelators |
| US5840979A (en) | 1997-07-14 | 1998-11-24 | University Of Saskatchewan | Aliphatic propargylamines as cellular rescue agents |
| GB9723078D0 (en) | 1997-10-31 | 1998-01-07 | Cerebrus Ltd | Chemical compounds |
| US20020137786A1 (en) | 1998-02-12 | 2002-09-26 | William G. Tatton | Deprenyl compounds to treat viral infections and reduce tissue damage associated therewith |
| EP1006108A1 (en) * | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
| EP1185259A1 (en) | 1999-04-29 | 2002-03-13 | MERCK PATENT GmbH | Glycine cleavage system inhibitors as potential antipsychotics |
| IL130324A0 (en) | 1999-06-07 | 2000-06-01 | Yeda Res & Dev | Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators |
| US20020019421A1 (en) | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
-
2003
- 2003-11-07 EP EP03773953A patent/EP1565185A4/en not_active Withdrawn
- 2003-11-07 US US10/534,357 patent/US8058442B2/en not_active Expired - Fee Related
- 2003-11-07 CA CA2505476A patent/CA2505476C/en not_active Expired - Fee Related
- 2003-11-07 AU AU2003282337A patent/AU2003282337B2/en not_active Ceased
- 2003-11-07 JP JP2005502148A patent/JP4757024B2/ja not_active Expired - Fee Related
- 2003-11-07 WO PCT/IL2003/000932 patent/WO2004041151A2/en not_active Ceased
-
2005
- 2005-05-05 IL IL168419A patent/IL168419A/en active IP Right Grant
-
2010
- 2010-10-25 JP JP2010238156A patent/JP2011079834A/ja not_active Abandoned
-
2011
- 2011-11-14 US US13/296,061 patent/US8685955B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515599A5 (https=) | ||
| JP7194530B2 (ja) | ペプチド及びペプチド関連化合物の高浸透性プロドラッグ組成物 | |
| EP0610487B1 (de) | Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| US9376381B2 (en) | High penetration prodrug compositions of peptides and peptide-related compounds | |
| EP0804463A1 (de) | Neurokinin (tachykinin)-antagonisten | |
| JP2008522981A5 (https=) | ||
| CA2982392C (en) | AQUEOUS COMPOSITION OF DENTAL GLASS IONOMER | |
| CA3188410A1 (en) | Conjugated hepcidin mimetics | |
| JP2024516371A5 (https=) | ||
| US12331016B2 (en) | Multi-arm single molecular weight polyethylene glycol active derivative and application thereof | |
| SK11242002A3 (sk) | Zlúčenina, spôsob prípravy zlúčeniny, farmaceutický prostriedok a spôsob liečenia rakoviny | |
| JP2013516424A (ja) | シクロスポリン類似体 | |
| WO2006077170A1 (en) | Use of aminodithiol as a reducing agent for hair perming | |
| JP2012524775A5 (https=) | ||
| AU765660B2 (en) | Ring modified cyclic peptide analogs | |
| JPH07502255A (ja) | 抗ウイルス化合物類 | |
| WO2007055578A1 (en) | Cyclic antimicrobial peptides derived from lactoferrin | |
| HUT76483A (en) | Derivatives of gamma-amino-alfa,beta-alkenyl sulfonic acids, utilization of the same in the synthesis of pseudopeptides and process for their preparation | |
| JP4841161B2 (ja) | ケラチン線維の永久矯正へのジメルカプトアミドの使用 | |
| CN116209448A (zh) | 阳离子甾族抗微生物化合物和制造此类化合物的方法 | |
| DE68923592T2 (de) | HIV Protease-Hemmer. | |
| CN116209669A (zh) | 具有内源性基团的阳离子甾体抗微生物化合物 | |
| US20100022478A1 (en) | Chiral compounds substituted with phosphonate acid ester functions or phosphonic acid functions | |
| RU2004128444A (ru) | Способы и композиции для лечения желудочно-кишечной токсичности, вызванной цитодеструктивной терапией | |
| JP2005510559A5 (https=) |